Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) — Shape Therapeutics Inc. (ShapeTX), the RNA technology company…
News
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Opus Genetics Leadership to Present at 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today…
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available…
Agenus Makes Senior Regulatory and Clinical Appointments
Patricia Carlos named Chief Regulatory, Quality, and Safety Officer Todd Yancey, MD named Senior Global…
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
Day One Appoints Garry Nicholson as Chairman of the Board of Directors
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a…
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
– Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb –– BMS-986249 Phase 2 study…
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the…
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Eosinophilic Esophagitis
Topline data anticipated around year-end 2022 NEW ORLEANS and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE)…
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022
Unique, intra-articular administration of AMB-05X yielded sustained, high synovial concentrations with low systemic exposures and…
SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — SOTIO Biotech, a clinical stage immuno-oncology company…
SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology
BILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ:…
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for…
Arbor Biotechnologies Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies today announced that Fierce Biotech…
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical…